Literature DB >> 16864176

LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.

Marianne Kyndi1, Jan Alsner, Lise Lotte Hansen, Flemming Brandt Sørensen, Jens Overgaard.   

Abstract

Mutations in the TP53 gene are a well-documented strong prognostic factor in breast cancer. A prognostic value of the Arg72Pro polymorphism of the TP53 gene is more contradictory. We assessed TP53 mutations and genotypes of the Arg72Pro polymorphism in a study including 204 Danish women. Patients with mutations in the TP53 gene had a significant reduction in disease-free survival of breast cancer (p < 0.0001). Genotypes of the Arg72Pro polymorphism were neither significantly associated with TP53 mutations nor with disease-free survival (p = 0.4). Among heterozygous patients a reduction in disease-free survival was found for patients with LOH and retention of the Pro allele as compared to patients with LOH and retention of the Arg allele and patients with no LOH (p = 0.05). In conclusion, we find a highly significant prognostic value of TP53 mutations but find a possible prognostic value of the Arg72Pro polymorphism only related to LOH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864176     DOI: 10.1080/02841860600660811

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Authors:  Patricia Rodrigues; Jessica Furriol; Eduardo Tormo; Sandra Ballester; Ana Lluch; Pilar Eroles
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

2.  Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.

Authors:  Marjanka K Schmidt; Johanna Tommiska; Annegien Broeks; Flora E van Leeuwen; Laura J Van't Veer; Paul D P Pharoah; Douglas F Easton; Mitul Shah; Manjeet Humphreys; Thilo Dörk; Scarlett A Reincke; Rainer Fagerholm; Carl Blomqvist; Heli Nevanlinna
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466

3.  Refined mapping of loss of heterozygosity on 1q31.1-32.1 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Guo-Qiang Qiu; Jun-Wei Fan; Xiao-Liang Wang; Hua-Mei Tang; Li Huang; Yu-Hao Sun; Zhi-Hai Peng
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

4.  Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population.

Authors:  Naseem Akhter; Sajad A Dar; Shilpi Chattopadhyay; Shafiul Haque; Razique Anwer; Mohd Wahid; Arshad Jawed; Mohtashim Lohani; Raju K Mandal; N K Shukla; Yasir Abdul; Syed Akhtar Husain
Journal:  Curr Genomics       Date:  2018-08       Impact factor: 2.236

Review 5.  Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy.

Authors:  Xiaonan Zhang; Tobias Sjöblom
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

6.  Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls.

Authors:  Wenlei Zhuo; Yunsong Zhang; Zhaolan Xiang; Lei Cai; Zhengtang Chen
Journal:  J Exp Clin Cancer Res       Date:  2009-08-14

7.  Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC).

Authors:  Marica Garziera; Erika Cecchin; Giorgio Giorda; Roberto Sorio; Simona Scalone; Elena De Mattia; Rossana Roncato; Sara Gagno; Elena Poletto; Loredana Romanato; Fabrizio Ecca; Vincenzo Canzonieri; Giuseppe Toffoli
Journal:  Cells       Date:  2019-10-01       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.